Literature DB >> 14656611

Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism.

Rossella Marcucci1, Agatina Alessandrello Liotta, Anna Paola Cellai, Angela Rogolino, Anna Maria Gori, Betti Giusti, Daniela Poli, Sandra Fedi, Rosanna Abbate, Domenico Prisco.   

Abstract

PURPOSE: Elevated lipoprotein(a) [Lp(a)] levels are a recognized risk factor for cardiovascular disease; however, little is known about their effects on venous thromboembolism.
METHODS: We conducted a case-control study of 603 adult patients with a history of venous thromboembolism (at least 6 months after the acute event) and 430 healthy subjects. We measured Lp(a), homocysteine, and antithrombin levels, factor V Leiden and factor II (prothrombin) polymorphisms, and anticardiolipin antibodies.
RESULTS: Lp(a) levels >300 mg/L were found in 24% (n = 146) of the patients and in 13% (n = 58) of the controls (P = 0.005). In a multivariate analysis adjusted for acquired and hemostasis-related risk factors, there was an independent association between elevated (>300 mg/L) Lp(a) levels and venous thromboembolism (odds ratio = 2.1; 95% confidence interval: 1.4 to 3.2; P = 0.002). These results were confirmed in the 341 patients with idiopathic venous thromboembolism, as well as in those with recurrent thromboembolism.
CONCLUSION: These results show that Lp(a) is an independent risk factor for venous thromboembolism in adults, suggesting that it may be involved in the pathogenesis of idiopathic and recurrent disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14656611     DOI: 10.1016/j.amjmed.2003.06.005

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  21 in total

1.  Can venous thromboembolism navigate the prevention of cardiovascular complications?

Authors:  Alena Shantsila; Gregory Y H Lip
Journal:  Ann Transl Med       Date:  2015-06

2.  Elevated body mass index and risk of postoperative CSF leak following transsphenoidal surgery.

Authors:  Brian J Dlouhy; Karthik Madhavan; John D Clinger; Ambur Reddy; Jeffrey D Dawson; Erin K O'Brien; Eugene Chang; Scott M Graham; Jeremy D W Greenlee
Journal:  J Neurosurg       Date:  2012-03-23       Impact factor: 5.115

Review 3.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.

Authors:  Børge G Nordestgaard; Anne Langsted
Journal:  J Lipid Res       Date:  2016-09-27       Impact factor: 5.922

Review 4.  Epidemiology of venous thromboembolism.

Authors:  John A Heit
Journal:  Nat Rev Cardiol       Date:  2015-06-16       Impact factor: 32.419

Review 5.  Is there a Link Between Atherothrombosis and Deep Venous Thrombosis?

Authors:  Maria-Cristina Andrei; Aurel Andercou
Journal:  Maedica (Buchar)       Date:  2014-03

6.  Metabolic syndrome and risk of venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology.

Authors:  L M Steffen; M Cushman; J M Peacock; S R Heckbert; D R Jacobs; W D Rosamond; A R Folsom
Journal:  J Thromb Haemost       Date:  2009-01-19       Impact factor: 5.824

Review 7.  Lipoprotein(a) and atherosclerosis: new perspectives on the mechanism of action of an enigmatic lipoprotein.

Authors:  Marlys L Koschinsky
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

8.  Detrimental effects of niacin/laropiprant on microvascular reactivity and red cell deformability in patients with elevated lipoprotein(a) levels.

Authors:  Gabriele Cioni; Lucia Mannini; Alessandrello Agatina Liotta; Giovanna D'Alessandri; Cinzia Fatini; Brunella Bandinelli; Maria Costanzo; Rosanna Abbate; Rossella Marcucci
Journal:  J Thromb Thrombolysis       Date:  2016-04       Impact factor: 2.300

9.  Genetic risk factors in recurrent venous thromboembolism: A multilocus, population-based, prospective approach.

Authors:  Robert Y L Zee; Vadim Bubes; Sanjay Shrivastava; Paul M Ridker; Robert J Glynn
Journal:  Clin Chim Acta       Date:  2009-04       Impact factor: 3.786

10.  The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism.

Authors:  Christian T Ruff; Marc S Sabatine; Nicholas A Marston; Yared Gurmu; Giorgio E M Melloni; Marc Bonaca; Baris Gencer; Peter S Sever; Terje R Pedersen; Anthony C Keech; Carolina Roselli; Steven A Lubitz; Patrick T Ellinor; Michelle L O'Donoghue; Robert P Giugliano
Journal:  Circulation       Date:  2020-03-29       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.